Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation

E. Piovan, L. Bonaldi, S. Indraccolo, V. Tosello, C. Menin, F. Comacchio, L. Chieco-Bianchi, A. Amadori

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease develops in severe combined immunodeficient (SCID) mice inoculated with peripheral blood mononuclear cells (PBMC) from EBV+ individuals (SCID/hu mice). In this study, we investigated the contribution of EBV reactivation and de novo infection of B lymphocytes to tumor outgrowth in SCID/hu mice. Evaluation of BZLF-1, an early EBV activation transcript, in cells recovered from the mouse peritoneal cavity within 16 days following PBMC transfer did not reveal EBV reactivation, while BZLF-1 expression was only detected in tumor masses or in vitro established lymphoblastoid cell lines. To confirm these data by a different strategy, we coinjected PBMC from seropositive donors with purified B cells from seronegative donors of different sex. Fluorescence in situ hydridization analysis of the resulting tumor masses disclosed that the overwhelming majority of lymphoma cells originated from the seropositive donor, implying that no substantial in vivo production and transmission of virus had occurred. Further, treatment of SCID/hu mice with ganciclovir did not prevent lymphoma development. Our results suggest that in the SCID/hu mouse, early EBV replication and secondary infection of bystander B cells does not occur, and that the direct outgrowth of the transformed B lymphocytes present within the PBMC inoculum is the predominant mechanism, which leads to lymphoma generation in this experimental model.

Original languageEnglish
Pages (from-to)1643-1649
Number of pages7
JournalLeukemia
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

SCID Mice
Human Herpesvirus 4
Blood Cells
B-Lymphocytes
Lymphoma
Neoplasms
Virus Activation
Ganciclovir
Epstein-Barr Virus Infections
Peritoneal Cavity
Virus Replication
Coinfection
Theoretical Models
Fluorescence
Viruses
Cell Line
Infection

Keywords

  • BZLF-1
  • EBV
  • FISH
  • Lymphoma
  • SCID mice

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

@article{35cd99639025493cb88b8b93c3b1a6f7,
title = "Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation",
abstract = "Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease develops in severe combined immunodeficient (SCID) mice inoculated with peripheral blood mononuclear cells (PBMC) from EBV+ individuals (SCID/hu mice). In this study, we investigated the contribution of EBV reactivation and de novo infection of B lymphocytes to tumor outgrowth in SCID/hu mice. Evaluation of BZLF-1, an early EBV activation transcript, in cells recovered from the mouse peritoneal cavity within 16 days following PBMC transfer did not reveal EBV reactivation, while BZLF-1 expression was only detected in tumor masses or in vitro established lymphoblastoid cell lines. To confirm these data by a different strategy, we coinjected PBMC from seropositive donors with purified B cells from seronegative donors of different sex. Fluorescence in situ hydridization analysis of the resulting tumor masses disclosed that the overwhelming majority of lymphoma cells originated from the seropositive donor, implying that no substantial in vivo production and transmission of virus had occurred. Further, treatment of SCID/hu mice with ganciclovir did not prevent lymphoma development. Our results suggest that in the SCID/hu mouse, early EBV replication and secondary infection of bystander B cells does not occur, and that the direct outgrowth of the transformed B lymphocytes present within the PBMC inoculum is the predominant mechanism, which leads to lymphoma generation in this experimental model.",
keywords = "BZLF-1, EBV, FISH, Lymphoma, SCID mice",
author = "E. Piovan and L. Bonaldi and S. Indraccolo and V. Tosello and C. Menin and F. Comacchio and L. Chieco-Bianchi and A. Amadori",
year = "2003",
month = "8",
day = "1",
doi = "10.1038/sj.leu.2403005",
language = "English",
volume = "17",
pages = "1643--1649",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation

AU - Piovan, E.

AU - Bonaldi, L.

AU - Indraccolo, S.

AU - Tosello, V.

AU - Menin, C.

AU - Comacchio, F.

AU - Chieco-Bianchi, L.

AU - Amadori, A.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease develops in severe combined immunodeficient (SCID) mice inoculated with peripheral blood mononuclear cells (PBMC) from EBV+ individuals (SCID/hu mice). In this study, we investigated the contribution of EBV reactivation and de novo infection of B lymphocytes to tumor outgrowth in SCID/hu mice. Evaluation of BZLF-1, an early EBV activation transcript, in cells recovered from the mouse peritoneal cavity within 16 days following PBMC transfer did not reveal EBV reactivation, while BZLF-1 expression was only detected in tumor masses or in vitro established lymphoblastoid cell lines. To confirm these data by a different strategy, we coinjected PBMC from seropositive donors with purified B cells from seronegative donors of different sex. Fluorescence in situ hydridization analysis of the resulting tumor masses disclosed that the overwhelming majority of lymphoma cells originated from the seropositive donor, implying that no substantial in vivo production and transmission of virus had occurred. Further, treatment of SCID/hu mice with ganciclovir did not prevent lymphoma development. Our results suggest that in the SCID/hu mouse, early EBV replication and secondary infection of bystander B cells does not occur, and that the direct outgrowth of the transformed B lymphocytes present within the PBMC inoculum is the predominant mechanism, which leads to lymphoma generation in this experimental model.

AB - Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease develops in severe combined immunodeficient (SCID) mice inoculated with peripheral blood mononuclear cells (PBMC) from EBV+ individuals (SCID/hu mice). In this study, we investigated the contribution of EBV reactivation and de novo infection of B lymphocytes to tumor outgrowth in SCID/hu mice. Evaluation of BZLF-1, an early EBV activation transcript, in cells recovered from the mouse peritoneal cavity within 16 days following PBMC transfer did not reveal EBV reactivation, while BZLF-1 expression was only detected in tumor masses or in vitro established lymphoblastoid cell lines. To confirm these data by a different strategy, we coinjected PBMC from seropositive donors with purified B cells from seronegative donors of different sex. Fluorescence in situ hydridization analysis of the resulting tumor masses disclosed that the overwhelming majority of lymphoma cells originated from the seropositive donor, implying that no substantial in vivo production and transmission of virus had occurred. Further, treatment of SCID/hu mice with ganciclovir did not prevent lymphoma development. Our results suggest that in the SCID/hu mouse, early EBV replication and secondary infection of bystander B cells does not occur, and that the direct outgrowth of the transformed B lymphocytes present within the PBMC inoculum is the predominant mechanism, which leads to lymphoma generation in this experimental model.

KW - BZLF-1

KW - EBV

KW - FISH

KW - Lymphoma

KW - SCID mice

UR - http://www.scopus.com/inward/record.url?scp=0041853566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041853566&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403005

DO - 10.1038/sj.leu.2403005

M3 - Article

C2 - 12886254

AN - SCOPUS:0041853566

VL - 17

SP - 1643

EP - 1649

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -